Efficacy of splenectomy for patients with mantle cell non-Hodgkin's lymphoma

Yinlee Yoong, Paul J. Kurtin, Cristine Allmer, Susan Geyer, Thomas Matthew Habermann, David M. Nagorney, Thomas Elmer Witzig

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The purpose of this study was to define the role of splenectomy in patients (pts) with mantle cell lymphoma (MCL) with regard to improving cytopenias and symptoms of splenomegaly. 26 pts with MCL underwent splenectomy between January 1987 and October 1999 and were followed prospectively for hematologic response and operative morbidity and mortality. A positive response was defined at 1 month of follow-up as: a hemoglobin of ≥ 11.0 g/dl in a pt with a preoperative value <11.0 g/dl; or a platelet count of ≥100 × 109/L in a pt with a preoperative value <100 × 109/L. A positive hematologic response was achieved in 69.2% of pts with preoperative anemia, 90% with thrombocytopenia, and 50% with both anemia and thrombocytopenia. The peri- and post-operative morbidity were 3.8 and 19.2%, respectively, the operative mortality was 0%. The median duration of hospitalization was six days. Four (15.4%) pts have not required chemotherapy after splenectomy. Three of these four were previously untreated and they have maintained stable disease for eight years after splenectomy without chemotherapy. Eight additional pts did not require chemotherapy for > 13 months after splenectomy. These results suggest that splenectomy may provide durable remission in selected pts with refractory cytopenias or symptoms related to splenomegaly in pts with MCL. There is a subset of pts that have prolonged disease stabilization without the requirement for immediate chemotherapy after splenectomy.

Original languageEnglish (US)
Pages (from-to)1235-1241
Number of pages7
JournalLeukemia and Lymphoma
Volume42
Issue number6
DOIs
StatePublished - 2001

Fingerprint

Mantle-Cell Lymphoma
Splenectomy
Non-Hodgkin's Lymphoma
Splenomegaly
Hemoglobins
Morbidity
Drug Therapy
Mortality

Keywords

  • Chemotherapy
  • Mantle cell lymphoma
  • Non-Hodgkin's lymphoma
  • Splenectomy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Efficacy of splenectomy for patients with mantle cell non-Hodgkin's lymphoma. / Yoong, Yinlee; Kurtin, Paul J.; Allmer, Cristine; Geyer, Susan; Habermann, Thomas Matthew; Nagorney, David M.; Witzig, Thomas Elmer.

In: Leukemia and Lymphoma, Vol. 42, No. 6, 2001, p. 1235-1241.

Research output: Contribution to journalArticle

Yoong, Yinlee ; Kurtin, Paul J. ; Allmer, Cristine ; Geyer, Susan ; Habermann, Thomas Matthew ; Nagorney, David M. ; Witzig, Thomas Elmer. / Efficacy of splenectomy for patients with mantle cell non-Hodgkin's lymphoma. In: Leukemia and Lymphoma. 2001 ; Vol. 42, No. 6. pp. 1235-1241.
@article{cfbc4744d6fe4b92ab72c1b4517714de,
title = "Efficacy of splenectomy for patients with mantle cell non-Hodgkin's lymphoma",
abstract = "The purpose of this study was to define the role of splenectomy in patients (pts) with mantle cell lymphoma (MCL) with regard to improving cytopenias and symptoms of splenomegaly. 26 pts with MCL underwent splenectomy between January 1987 and October 1999 and were followed prospectively for hematologic response and operative morbidity and mortality. A positive response was defined at 1 month of follow-up as: a hemoglobin of ≥ 11.0 g/dl in a pt with a preoperative value <11.0 g/dl; or a platelet count of ≥100 × 109/L in a pt with a preoperative value <100 × 109/L. A positive hematologic response was achieved in 69.2{\%} of pts with preoperative anemia, 90{\%} with thrombocytopenia, and 50{\%} with both anemia and thrombocytopenia. The peri- and post-operative morbidity were 3.8 and 19.2{\%}, respectively, the operative mortality was 0{\%}. The median duration of hospitalization was six days. Four (15.4{\%}) pts have not required chemotherapy after splenectomy. Three of these four were previously untreated and they have maintained stable disease for eight years after splenectomy without chemotherapy. Eight additional pts did not require chemotherapy for > 13 months after splenectomy. These results suggest that splenectomy may provide durable remission in selected pts with refractory cytopenias or symptoms related to splenomegaly in pts with MCL. There is a subset of pts that have prolonged disease stabilization without the requirement for immediate chemotherapy after splenectomy.",
keywords = "Chemotherapy, Mantle cell lymphoma, Non-Hodgkin's lymphoma, Splenectomy",
author = "Yinlee Yoong and Kurtin, {Paul J.} and Cristine Allmer and Susan Geyer and Habermann, {Thomas Matthew} and Nagorney, {David M.} and Witzig, {Thomas Elmer}",
year = "2001",
doi = "10.1080/10428190127511",
language = "English (US)",
volume = "42",
pages = "1235--1241",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Efficacy of splenectomy for patients with mantle cell non-Hodgkin's lymphoma

AU - Yoong, Yinlee

AU - Kurtin, Paul J.

AU - Allmer, Cristine

AU - Geyer, Susan

AU - Habermann, Thomas Matthew

AU - Nagorney, David M.

AU - Witzig, Thomas Elmer

PY - 2001

Y1 - 2001

N2 - The purpose of this study was to define the role of splenectomy in patients (pts) with mantle cell lymphoma (MCL) with regard to improving cytopenias and symptoms of splenomegaly. 26 pts with MCL underwent splenectomy between January 1987 and October 1999 and were followed prospectively for hematologic response and operative morbidity and mortality. A positive response was defined at 1 month of follow-up as: a hemoglobin of ≥ 11.0 g/dl in a pt with a preoperative value <11.0 g/dl; or a platelet count of ≥100 × 109/L in a pt with a preoperative value <100 × 109/L. A positive hematologic response was achieved in 69.2% of pts with preoperative anemia, 90% with thrombocytopenia, and 50% with both anemia and thrombocytopenia. The peri- and post-operative morbidity were 3.8 and 19.2%, respectively, the operative mortality was 0%. The median duration of hospitalization was six days. Four (15.4%) pts have not required chemotherapy after splenectomy. Three of these four were previously untreated and they have maintained stable disease for eight years after splenectomy without chemotherapy. Eight additional pts did not require chemotherapy for > 13 months after splenectomy. These results suggest that splenectomy may provide durable remission in selected pts with refractory cytopenias or symptoms related to splenomegaly in pts with MCL. There is a subset of pts that have prolonged disease stabilization without the requirement for immediate chemotherapy after splenectomy.

AB - The purpose of this study was to define the role of splenectomy in patients (pts) with mantle cell lymphoma (MCL) with regard to improving cytopenias and symptoms of splenomegaly. 26 pts with MCL underwent splenectomy between January 1987 and October 1999 and were followed prospectively for hematologic response and operative morbidity and mortality. A positive response was defined at 1 month of follow-up as: a hemoglobin of ≥ 11.0 g/dl in a pt with a preoperative value <11.0 g/dl; or a platelet count of ≥100 × 109/L in a pt with a preoperative value <100 × 109/L. A positive hematologic response was achieved in 69.2% of pts with preoperative anemia, 90% with thrombocytopenia, and 50% with both anemia and thrombocytopenia. The peri- and post-operative morbidity were 3.8 and 19.2%, respectively, the operative mortality was 0%. The median duration of hospitalization was six days. Four (15.4%) pts have not required chemotherapy after splenectomy. Three of these four were previously untreated and they have maintained stable disease for eight years after splenectomy without chemotherapy. Eight additional pts did not require chemotherapy for > 13 months after splenectomy. These results suggest that splenectomy may provide durable remission in selected pts with refractory cytopenias or symptoms related to splenomegaly in pts with MCL. There is a subset of pts that have prolonged disease stabilization without the requirement for immediate chemotherapy after splenectomy.

KW - Chemotherapy

KW - Mantle cell lymphoma

KW - Non-Hodgkin's lymphoma

KW - Splenectomy

UR - http://www.scopus.com/inward/record.url?scp=0035694815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035694815&partnerID=8YFLogxK

U2 - 10.1080/10428190127511

DO - 10.1080/10428190127511

M3 - Article

C2 - 11911404

AN - SCOPUS:0035694815

VL - 42

SP - 1235

EP - 1241

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 6

ER -